دورية أكاديمية
أعرض في EDS

Long-acting PGE2 and Lisinopril Mitigate H-ARS.

التفاصيل البيبلوغرافية
العنوان: Long-acting PGE2 and Lisinopril Mitigate H-ARS.
المؤلفون: Saunders J; Center for Pediatric Research, University of Rochester Medical Center, Rochester, New York.; Departments of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York., Niswander LM; Center for Pediatric Research, University of Rochester Medical Center, Rochester, New York.; Departments of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York., McGrath KE; Center for Pediatric Research, University of Rochester Medical Center, Rochester, New York.; Department of Pediatrics, University of Rochester Medical Center, Rochester, New York., Koniski A; Center for Pediatric Research, University of Rochester Medical Center, Rochester, New York.; Department of Pediatrics, University of Rochester Medical Center, Rochester, New York., Catherman SC; Center for Pediatric Research, University of Rochester Medical Center, Rochester, New York.; Department of Pediatrics, University of Rochester Medical Center, Rochester, New York., Ture SK; Aab Cardiovascular Research Institute, University of Rochester Medical Center, Rochester, New York., Medhora M; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin., Kingsley PD; Center for Pediatric Research, University of Rochester Medical Center, Rochester, New York.; Department of Pediatrics, University of Rochester Medical Center, Rochester, New York., Calvi LM; Department of Medicine, University of Rochester Medical Center, Rochester, New York.; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York., Williams JP; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.; Department of Environmental Medicine, University of Rochester Medical Center, Rochester, New York., Morrell CN; Aab Cardiovascular Research Institute, University of Rochester Medical Center, Rochester, New York.; Department of Medicine, University of Rochester Medical Center, Rochester, New York., Palis J; Center for Pediatric Research, University of Rochester Medical Center, Rochester, New York.; Department of Pediatrics, University of Rochester Medical Center, Rochester, New York.; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.
المصدر: Radiation research [Radiat Res] 2021 Sep 01; Vol. 196 (3), pp. 284-296.
نوع المنشور: Comparative Study; Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Radiation Research Society Country of Publication: United States NLM ID: 0401245 Publication Model: Print Cited Medium: Internet ISSN: 1938-5404 (Electronic) Linking ISSN: 00337587 NLM ISO Abbreviation: Radiat Res Subsets: MEDLINE
أسماء مطبوعة: Publication: Bozeman, MT : Radiation Research Society
Original Publication: Charlottesville, VA : Kluge Carden Jennnings Pub. Co.
مواضيع طبية MeSH: 16,16-Dimethylprostaglandin E2/*therapeutic use , Acute Radiation Syndrome/*drug therapy , Angiotensin-Converting Enzyme Inhibitors/*therapeutic use , Blood Platelets/*drug effects , Endothelial Cells/*drug effects , Hemorrhagic Disorders/*drug therapy , Lisinopril/*therapeutic use , Megakaryocytes/*drug effects , Thrombocytopenia/*drug therapy , Thrombopoiesis/*drug effects, Acute Radiation Syndrome/complications ; Animals ; Blood Platelets/radiation effects ; Bone Marrow/drug effects ; Bone Marrow/radiation effects ; C-Reactive Protein/analysis ; Cesium Radioisotopes ; Drug Evaluation, Preclinical ; Endothelial Cells/radiation effects ; Endothelium, Vascular/drug effects ; Endothelium, Vascular/radiation effects ; Female ; Gamma Rays/adverse effects ; Hemorrhagic Disorders/etiology ; Megakaryocytes/radiation effects ; Mice ; Mice, Inbred C57BL ; P-Selectin/analysis ; Platelet Aggregation/drug effects ; Platelet Aggregation/radiation effects ; Platelet Factor 4/analysis ; Radiation Injuries, Experimental/drug therapy ; Radiation Injuries, Experimental/etiology ; Thrombocytopenia/etiology ; Thrombopoiesis/radiation effects ; Whole-Body Irradiation ; von Willebrand Factor/analysis
مستخلص: Thrombocytopenia is a major complication in hematopoietic-acute radiation syndrome (H-ARS) that increases the risk of mortality from uncontrolled hemorrhage. There is a great demand for new therapies to improve survival and mitigate bleeding in H-ARS. Thrombopoiesis requires interactions between megakaryocytes (MKs) and endothelial cells. 16, 16-dimethyl prostaglandin E2 (dmPGE2), a longer-acting analogue of PGE2, promotes hematopoietic recovery after total-body irradiation (TBI), and various angiotensin-converting enzyme (ACE) inhibitors mitigate endothelial injury after radiation exposure. Here, we tested a combination therapy of dmPGE2 and lisinopril to mitigate thrombocytopenia in murine models of H-ARS following TBI. After 7.75 Gy TBI, dmPGE2 and lisinopril each increased survival relative to vehicle controls. Importantly, combined dmPGE2 and lisinopril therapy enhanced survival greater than either individual agent. Studies performed after 4 Gy TBI revealed reduced numbers of marrow MKs and circulating platelets. In addition, sublethal TBI induced abnormalities both in MK maturation and in in vitro and in vivo platelet function. dmPGE2, alone and in combination with lisinopril, improved recovery of marrow MKs and peripheral platelets. Finally, sublethal TBI transiently reduced the number of marrow Lin-CD45-CD31+Sca-1- sinusoidal endothelial cells, while combined dmPGE2 and lisinopril treatment, but not single-agent treatment, accelerated their recovery. Taken together, these data support the concept that combined dmPGE2 and lisinopril therapy improves thrombocytopenia and survival by promoting recovery of the MK lineage, as well as the MK niche, in the setting of H-ARS.
(©2021 by Radiation Research Society. All rights of reproduction in any form reserved.)
References: Chest. 2011 Feb;139(2):271-278. (PMID: 21071526)
Semin Thromb Hemost. 2016 Apr;42(3):191-204. (PMID: 26926581)
Blood. 2008 Feb 1;111(3):981-6. (PMID: 18223171)
J Clin Invest. 2021 Jan 4;131(1):. (PMID: 33079726)
Blood. 2008 Apr 1;111(7):3522-30. (PMID: 18218855)
Health Phys. 2016 Nov;111(5):410-9. (PMID: 27682899)
Br J Radiol. 1987 Dec;60(720):1159-63. (PMID: 3690163)
Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16900-5. (PMID: 17075060)
Cardiovasc Res. 2015 Aug 1;107(3):331-9. (PMID: 25994174)
Radiat Res. 2010 Apr;173(4):557-78. (PMID: 20334528)
Blood. 1965 Dec;26(6):720-31. (PMID: 5844145)
EMBO Rep. 2018 Aug;19(8):. (PMID: 29848511)
Sci Rep. 2019 Feb 18;9(1):2198. (PMID: 30778109)
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):408-17. (PMID: 21075553)
J Clin Invest. 1969 Jun;48(6):963-74. (PMID: 5814231)
Blood. 1968 Jul;32(1):102-10. (PMID: 5690593)
Health Phys. 2010 Jun;98(6):825-32. (PMID: 20445389)
N Engl J Med. 2010 Feb 18;362(7):600-13. (PMID: 20164484)
Health Phys. 2012 Oct;103(4):356-66. (PMID: 22929468)
Blood. 2009 Nov 5;114(19):4054-63. (PMID: 19726721)
J Clin Invest. 2005 Dec;115(12):3339-47. (PMID: 16322778)
Int Immunopharmacol. 2007 Apr;7(4):500-5. (PMID: 17321473)
Blood. 2016 Feb 4;127(5):616-25. (PMID: 26637787)
Oncology (Williston Park). 2015 Apr;29(4):282-94. (PMID: 25952492)
Exp Cell Res. 2014 Dec 10;329(2):220-6. (PMID: 25094063)
J Cell Biol. 2013 Jun 10;201(6):785-96. (PMID: 23751492)
Blood. 2014 Jul 10;124(2):277-86. (PMID: 24735964)
Expert Opin Drug Discov. 2015 May;10(5):497-517. (PMID: 25819367)
Nature. 2017 Apr 6;544(7648):105-109. (PMID: 28329764)
Rep Pract Oncol Radiother. 2011 Jul 06;16(4):123-30. (PMID: 24376969)
J Intensive Care Med. 2007 Mar-Apr;22(2):105-10. (PMID: 17469241)
Ann Intern Med. 2015 Feb 3;162(3):205-13. (PMID: 25383671)
Ann Intern Med. 2004 Jun 15;140(12):1037-51. (PMID: 15197022)
Blood. 2007 Aug 15;110(4):1153-60. (PMID: 17495129)
Blood Adv. 2019 Jan 8;3(1):72-82. (PMID: 30622145)
Stem Cells. 2013 Feb;31(2):372-83. (PMID: 23169593)
Disaster Med Public Health Prep. 2011 Oct;5(3):183-201. (PMID: 21986999)
Ann Emerg Med. 2005 Jun;45(6):643-52. (PMID: 15940101)
Blood. 2013 Oct 24;122(17):3074-81. (PMID: 23996087)
Exp Hematol. 2010 Apr;38(4):270-81. (PMID: 20116413)
Nat Med. 2004 Jan;10(1):64-71. (PMID: 14702636)
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):292-6. (PMID: 22104363)
Br J Haematol. 2009 Apr;145(1):24-33. (PMID: 19222477)
Blood Cells Mol Dis. 2013 Mar;50(3):147-53. (PMID: 23206586)
J Radiat Res. 2017 Jul 1;58(4):456-463. (PMID: 28402443)
Clin Phys Physiol Meas. 1984 Aug;5(3):145-70. (PMID: 6488722)
Thromb Res. 2014 May;133 Suppl 2:S63-9. (PMID: 24862148)
J Biochem. 1978 Dec;84(6):1485-94. (PMID: 216666)
Thromb J. 2016 Oct 4;14(Suppl 1):29. (PMID: 27766055)
Transfus Med Rev. 2004 Jul;18(3):153-67. (PMID: 15248165)
J Am Assoc Lab Anim Sci. 2009 Jan;48(1):11-22. (PMID: 19245745)
Health Phys. 2005 Nov;89(5):505-12. (PMID: 16217194)
Int Immunopharmacol. 2013 Feb;15(2):348-56. (PMID: 23328620)
Blood. 2009 May 28;113(22):5444-55. (PMID: 19324903)
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3782-7. (PMID: 15738422)
Br J Radiol. 1989 Apr;62(736):348-54. (PMID: 2540864)
Radiat Res. 2016 Aug;186(2):99-111. (PMID: 27387859)
Cell Stem Cell. 2009 Mar 6;4(3):263-74. (PMID: 19265665)
Science. 2007 Sep 21;317(5845):1767-70. (PMID: 17885137)
Cytometry A. 2014 Apr;85(4):302-12. (PMID: 24616422)
Crit Rev Oncol Hematol. 2003 Oct 15;48(Suppl):S13-6. (PMID: 14563516)
Blood. 1965 Jul;26:20-35. (PMID: 14314398)
معلومات مُعتمدة: U01 AI107276 United States AI NIAID NIH HHS; U19 AI067773 United States AI NIAID NIH HHS; U19 AI091036 United States AI NIAID NIH HHS
المشرفين على المادة: 0 (Angiotensin-Converting Enzyme Inhibitors)
0 (Cesium Radioisotopes)
0 (P-Selectin)
0 (von Willebrand Factor)
37270-94-3 (Platelet Factor 4)
4T2E65IAR7 (Cesium-137)
9007-41-4 (C-Reactive Protein)
E7199S1YWR (Lisinopril)
M790V82VAC (16,16-Dimethylprostaglandin E2)
تواريخ الأحداث: Date Created: 20210621 Date Completed: 20211014 Latest Revision: 20220902
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8516355
DOI: 10.1667/RADE-20-00113.1
PMID: 34153091
قاعدة البيانات: MEDLINE
الوصف
تدمد:1938-5404
DOI:10.1667/RADE-20-00113.1